A Phase 3 interventional study of Regorafenib and Nivolumab in Gastro-Oesophageal Cancer, sponsored by Australasian Gastro-Intestinal Trials Group. Completed at 94 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Australasian Gastro-Intestinal Trials Group · Phase 3, Interventional, and Treatment
How we know · 13 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing regorafenib in Neoplasm Metastasis — 2 open to participants now, 2 under way, none of them phase 3. regorafenib · Neoplasm Metastasis.
Among the 17 studies testing regorafenib in Neoplasm Metastasis, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 3 in phase 3, and was the 16th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →2 of the 17 studies testing regorafenib in Neoplasm Metastasis are open now, in 1 country. Recruiting first, the newest first:
Centre Leon Berard · Sites in France
Ages 18+
Institut Bergonié · Sites in France
Ages 18+
By country, each count listing its studies:
regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 3
First in 2012; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 462 is above the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 50 across the 17 interventional studies. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 17 have an industry lead sponsor. The 10 most frequent:
Australasian Gastro-Intestinal Trials Group is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
Australasian Gastro-Intestinal Trials Group has 2 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing regorafenib in Neoplasm Metastasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
The purpose of this international study is to determine if the combination of regorafenib and nivolumab is more effective than standard chemotherapy in prolonging overall survival in a broad group of participants with AGOC, who have progressed after treatment with standard anti-cancer therapy.
In the INTEGRATE study, regorafenib alone was shown to be effective in prolonging the progression-free period in people with AGOC following standard anti-cancer therapy (i.e. it delayed tumour growth), and demonstrated a potential benefit on long term survival. Recent research has shown the early results from this combination of regorafenib \& nivolumab may improve outcomes for cancer patients. INTEGRATE IIb will investigate this effect further in a larger group of participants with AGOC.
The study aims to determine:
i. Whether the combination of regorafenib/nivolumab is likely to help patients with AGOC live longer; ii. The effects of this treatment on progression-free survival; iii. The numbers of participants responding to the treatment iv. The effects of this treatment on quality of life v. The side effects and tolerability of this treatment vi. Molecular differences (e.g. variations in genes or proteins) that may account for the effects of this treatment vii. Differences in the costs of care for people on this treatment.
The Investigators plan to enrol 460 participants in the study from, but not limited to; Australia, South Korea, Japan, Taiwan, USA, Germany, Austria, Spain, and Italy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults (18 years or over) with or locally recurrent gastro-oesophageal cancer which:
Adequate liver function (Serum total ≤1.5 x ULN, and ≤ 1.5 x ULN, and (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) ≤2.5 x ULN (≤ 5 x ULN for participants with liver metastases)).
Participants being treated with an anti-coagulant, such as warfarin or heparin, will be allowed to participate provided that no prior evidence of an underlying abnormality in these parameters exists.
Exclusion Criteria:
History of another within 2 years prior to randomization. Participants with the following are eligible for this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the RegoNivo arm will; 1. self-administer 90mg (3x30mg) of regorafenib days 1-21 of each 28-day treatment cycle and; 2. receive intravenous nivolumab 240 mg day 1 of each 14 day cycle until disease progression or prohibitive adverse events as per protocol, given in hospital by infusion. After 2 months, patients whose disease is controlled may have nivolumab administered 480 mg every 28 days.
Drug: Regorafenib · Biological: Nivolumab
Participants in the control arm will receive investigator choice chemotherapy with any of the following agents * taxane (paclitaxel or docetaxel) * irinotecan or * oral trifluridine/tipiracil (TAS102) All treatment groups will receive Best Supportive Care (BSC).
Drug: Docetaxel · Drug: Paclitaxel · Drug: Irinotecan · Drug: Trifluridine/Tipracil
Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases
Also known as: Stivarga
human IgG4 monoclonal antibody inhibitor of PD-1
Also known as: Opdivo
Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc. microtubules, and simultaneously promotes assembly and inhibits disassembly of them
Also known as: Taxotere
Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division
Also known as: Abraxane
Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.
Also known as: Camptosar
The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
Also known as: Lonsurf
O/S
To determine the effect of RegoNivo on overall survival (OS) (death from any cause) in the overall study population and in the Asian sub-population. Overall survival is defined as the interval from the date of randomisation to date of death from any cause, or the date last known alive.
Time frame: From the date of randomisation to date of death from any cause or the date last known alive, assessed up to approximately 44 months.
Determine the Effect of RegoNivo on; PFS
A PFS (Progressive free survival) event is defined as the first occasion that either RECIST criteria and iRECIST for disease progression are met, a patient is judged to have progressed by the responsible investigator (in the event that no RECIST assessment is available) or death occurs. Progression is defined using RECIST v1.1 and iRECIST, as a 20% increase in the sum of the longest diameter of target lesions taking as reference the smallest sum of diameters recorded in the study (including baseline) and an absolute increase of at least 5mm. The appearance of one or more new lesions is also considered progression. In exceptional circumstances, unequivocal progression of non-target disease was accepted as evidence of disease progression, where the overall tumour burden has increased sufficiently to merit discontinuation of treatment or where the tumour burden appears to have increased by at least 73% in volume.
Time frame: From the date of randomisation to the date of first evidence of disease progression or death, whichever occurs first, assessed up to approximately 44 months.
Determine the Effect of RegoNivo on; OTRR
Number of participants achieving a Partial Response (PR) or Complete Response (CR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and iRECIST. Complete Response (CR): Disappearance of all target and non-target lesions and normalisation of any specified tumour markers Partial Response (PR): \>=30% decrease in the sum of diameters of target lesions (longest diameter for tumour lesions and short axis measure for target lymph nodes), taking as reference the baseline sum of diameters.
Time frame: From randomisation until disease progression, with tumour assessments performed every 8 weeks (±7 days), assessed up to approximately 44 months.
Deterioration-Free Survival (DFS) Based on Physical Function (EORTC QLQ-C30)
Quality of life (scores from participant-completed questionnaires) of participants on study EORTC QoL Questionnaire: QLQ-C30: Q1 - Q28, Min 1 Max 4, Higher Score = Worse QLQ-C30: Q29 \& Q30 Min 1 Max 7, Higher = Better Deterioration-Free Survival (DFS) rate based on Physical Function is defined as the percentage of participants who have not experienced deterioration, disease progression, death, or treatment discontinuation at the specified time point. Deterioration is defined as a ≥10-point decrease from baseline in the Physical Function scale of the EORTC QLQ-C30, without a subsequent ≥10-point improvement compared with baseline. Physical function is assessed using the EORTC QLQ-C30 Physical Function Scale to identify the percentage of participants who were deterioration-free at 6 months and 12 months.
Time frame: 6 months and 12 months after randomisation.
Deterioration-Free Survival Rate Based on Global Health Status (EORTC QLQ-C30)
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EORTC Quality of Life Questionnaire: EORTC QLQ-C30: Q1 - Q28, Min 1 Max 4, Higher Score = Worse EORTC QLQ-C30: Q29 \& Q30 Min 1 Max 7, Higher = Better Deterioration-Free Survival (DFS) rate based on Global Health Status is defined as the percentage of participants who have not experienced any of the following events by the specified time point; A ≥10-point deterioration from baseline in the Global Health Status/QoL scale of the EORTC QLQ-C30, without a subsequent ≥10-point improvement, disease progression, death from any cause or treatment discontinuation. Global Health Status is assessed using the EORTC QLQ-C30 Global Health Status to identify the percentage of participants who were deterioration free at 6 months and 12 months.
Time frame: 6 months and 12 months after randomisation
Determine the Effect of RegoNivo on; Safety
Safety (rates of adverse events) of participants on study
Time frame: From the first dose of study treatment until 30 days following the last dose of study treatment, up to approximately 44 months.
Prognostic Biomarker Identification for AGOC
To identify prognostic and predictive biomarkers (tissue and circulating) for study endpoints (relating to survival, response and safety).
Time frame: Up to 24 months following close of study.
Regorafenib Max Plasma Concentration Level Assessment (Cmax) Across Geographical Regions
To evaluate regorafenib Cmax in patient populations from different geographical regions (regorafenib levels).
Time frame: Up to 24 months following close of study.
Regorafenib Levels and Correlation to Treatment
To evaluate regorafenib levels and their correlation to outcomes in treatment
Time frame: Up to 24 months following close of study.
Participants were recruited from 73 clinical sites across Austria, Australia, Germany, Italy, Japan, Spain, South Korea, Taiwan and United States of America. Eligibility was confirmed through screening visits, and informed consent was obtained prior to any study procedures. Randomisation occurred between 05/05/2021 and 30/04/2024.
| Milestone | RegoNivo | Standard of Care |
|---|---|---|
| Started | 309 | 153 |
| Completed | 291 | 129 |
| Not completed | 18 | 24 |
To determine the effect of RegoNivo on overall survival (OS) (death from any cause) in the overall study population and in the Asian sub-population. Overall survival is defined as the interval from the date of randomisation to date of death from any cause, or the date last known alive.
| Months | RegoNivo | Standard of Care |
|---|---|---|
| O/S | 5.91 (5.16 to 6.80) | 6.28 (4.80 to 7.36) |
A PFS (Progressive free survival) event is defined as the first occasion that either RECIST criteria and iRECIST for disease progression are met, a patient is judged to have progressed by the responsible investigator (in the event that no RECIST assessment is available) or death occurs. Progression is defined using RECIST v1.1 and iRECIST, as a 20% increase in the sum of the longest diameter of target lesions taking as reference the smallest sum of diameters recorded in the study (including baseline) and an absolute increase of at least 5mm. The appearance of one or more new lesions is also considered progression. In exceptional circumstances, unequivocal progression of non-target disease was accepted as evidence of disease progression, where the overall tumour burden has increased sufficiently to merit discontinuation of treatment or where the tumour burden appears to have increased by at least 73% in volume.
| Months | RegoNivo | Standard of Care |
|---|---|---|
| Determine the Effect of RegoNivo on; PFS | 1.91 (1.84 to 2.04) | 1.87 (1.77 to 2.00) |
Number of participants achieving a Partial Response (PR) or Complete Response (CR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and iRECIST. Complete Response (CR): Disappearance of all target and non-target lesions and normalisation of any specified tumour markers Partial Response (PR): \>=30% decrease in the sum of diameters of target lesions (longest diameter for tumour lesions and short axis measure for target lymph nodes), taking as reference the baseline sum of diameters.
| Number of participants with CR or PR | RegoNivo | Standard of Care |
|---|---|---|
| Determine the Effect of RegoNivo on; OTRR | 23 | 4 |
Quality of life (scores from participant-completed questionnaires) of participants on study EORTC QoL Questionnaire: QLQ-C30: Q1 - Q28, Min 1 Max 4, Higher Score = Worse QLQ-C30: Q29 \& Q30 Min 1 Max 7, Higher = Better Deterioration-Free Survival (DFS) rate based on Physical Function is defined as the percentage of participants who have not experienced deterioration, disease progression, death, or treatment discontinuation at the specified time point. Deterioration is defined as a ≥10-point decrease from baseline in the Physical Function scale of the EORTC QLQ-C30, without a subsequent ≥10-point improvement compared with baseline. Physical function is assessed using the EORTC QLQ-C30 Physical Function Scale to identify the percentage of participants who were deterioration-free at 6 months and 12 months.
| Percentage of participants | RegoNivo | Standard of Care |
|---|---|---|
| DFS Rate at 6 Months (Physical Function) | 6.9 (4.4 to 10) | 6.3 (3.1 to 11) |
| DFS Rate at 12 Months (Physical Function) | 3.9 (2.1 to 6.5) | 0.7 (0.1 to 3.5) |
Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EORTC Quality of Life Questionnaire: EORTC QLQ-C30: Q1 - Q28, Min 1 Max 4, Higher Score = Worse EORTC QLQ-C30: Q29 \& Q30 Min 1 Max 7, Higher = Better Deterioration-Free Survival (DFS) rate based on Global Health Status is defined as the percentage of participants who have not experienced any of the following events by the specified time point; A ≥10-point deterioration from baseline in the Global Health Status/QoL scale of the EORTC QLQ-C30, without a subsequent ≥10-point improvement, disease progression, death from any cause or treatment discontinuation. Global Health Status is assessed using the EORTC QLQ-C30 Global Health Status to identify the percentage of participants who were deterioration free at 6 months and 12 months.
| Percentage of participants | RegoNivo | Standard of Care |
|---|---|---|
| DFS Rate at 6 Months (Global Health Status) | 6.9 (4.4 to 10) | 5.6 (2.6 to 10) |
| DFS Rate at 12 Months (Global Health Status) | 3.9 (2.1 to 6.5) | 0.7 (0.1 to 3.5) |
To identify prognostic and predictive biomarkers (tissue and circulating) for study endpoints (relating to survival, response and safety).
Results for this outcome have not been posted.
To evaluate regorafenib Cmax in patient populations from different geographical regions (regorafenib levels).
Results for this outcome have not been posted.
To evaluate regorafenib levels and their correlation to outcomes in treatment
Results for this outcome have not been posted.
Safety (rates of adverse events) of participants on study
| Participants | RegoNivo | Standard of Care |
|---|---|---|
| Any AE (Grade 1-5) | 293 | 127 |
| Any SAE (Grade 1-5) | 122 | 34 |
Collected over From the first dose of study treatment until 30 days following the last dose of study treatment, up to approximately 44 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RegoNivo | 262/309 (84.8%) | 122/300 (40.7%) | 293/300 (97.7%) |
| Standard of Care | 128/153 (83.7%) | 34/138 (24.6%) | 127/138 (92%) |
| Event | RegoNivo | Standard of Care |
|---|---|---|
| General disorders totalGastrointestinal disorders | 38/300 | 12/138 |
| General disorders totalInfections and infestations | 26/300 | 6/138 |
| General disorders totalGeneral disorders | 17/300 | 3/138 |
| General disorders totalRespiratory, thoracic and mediastinal disorders | 14/300 | 5/138 |
| General disorders totalSkin and subcutaneous tissue disorders | 12/300 | 0/138 |
| General disorders totalInvestigations | 8/300 | 4/138 |
| General disorders totalHepatobiliary disorders | 8/300 | 1/138 |
| General disorders totalMetabolism and nutrition disorders | 8/300 | 3/138 |
| General disorders totalBlood and lymphatic system disorders | 4/300 | 3/138 |
| General disorders totalMusculoskeletal and connective tissue disorders | 5/300 | 0/138 |
| Event | RegoNivo | Standard of Care |
|---|---|---|
| General disorders totalGastrointestinal disorders | 185/300 | 91/138 |
| General disorders totalGeneral disorders | 146/300 | 55/138 |
| General disorders totalInvestigations | 135/300 | 60/138 |
| General disorders totalSkin and subcutaneous tissue disorders | 121/300 | 21/138 |
| General disorders totalMetabolism and nutrition disorders | 106/300 | 39/138 |
| General disorders totalRespiratory, thoracic and mediastinal disorders | 84/300 | 18/138 |
| General disorders totalBlood and lymphatic system disorders | 46/300 | 37/138 |
| General disorders totalInfections and infestations | 68/300 | 25/138 |
| General disorders totalVascular disorders | 66/300 | 10/138 |
| General disorders totalMusculoskeletal and connective tissue disorders | 62/300 | 17/138 |
The baseline analysis participants matches the participant flow count
| Sex: Female, Male(Participants) | RegoNivo | Standard of Care | Total |
|---|---|---|---|
| Female | 83 | 39 | 122 |
| Male | 226 | 114 | 340 |
| Prior use of VEGF inhibitors(Participants) | RegoNivo | Standard of Care | Total |
|---|---|---|---|
| Number | 190 | 90 | 280 |
| Age, Customized(Participants) | RegoNivo | Standard of Care | Total |
|---|---|---|---|
| <=64 | 173 | 82 | 255 |
| >64 | 136 | 71 | 207 |
| Prior immunotherapy(Participants) | RegoNivo | Standard of Care | Total |
|---|---|---|---|
| Number | 102 | 50 | 152 |
| Race/Ethnicity, Customized(Participants) | RegoNivo | Standard of Care | Total |
|---|---|---|---|
| Asia | 147 | 73 | 220 |
| Rest of the world | 162 | 80 | 242 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2021 to primary completion in Jan 2025, 44 months.
Results were first posted in Jun 2026, 1 year 4 months after primary completion.
Of 55 non-industry phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 108. This study's 44 months is below that.
Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Regorafenib · Nivolumab
Australasian Gastro-Intestinal Trials Group